Avalyn Pharma Joins April Investor Conference with Inhaled Therapy Focus

Prime Highlights

• Avalyn Pharma to host the Citi Biotech Private Access Day on April 24, 2025.
• Company-sponsored virtual one-to-one investor meetings will be conducted to highlight its pipeline of inhaled drugs.

Key Facts

• Lead product AP01 is currently in Phase 2b trials for Progressive Pulmonary Fibrosis (PPF).
• AP02, a nintedanib inhalation, is in Phase 1 studies for Idiopathic Pulmonary Fibrosis (IPF).

Key Background

Avalyn Pharma Inc., a US clinical-stage biopharmaceutical firm, is charting the course towards inhaled therapeutics for more serious lung conditions like pulmonary fibrosis. Such conditions, progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), bring about fibrosis of the lung tissue, which reduces respiratory capacity and quality of life. With conventional oral drugs limited by systemic side effects, Avalyn promises to revolutionize treatment by way of localized drug delivery.

Its top asset, AP01, is a refined inhalation form of pirfenidone. This has already been under investigation for the PPF indication in an ongoing Phase 2b study, MIST (Maximizing Inhaled Safety and Tolerability). The product has already been assessed in more than 150 patients and shown a tolerable safety profile with reassuring indications of effectiveness. By acting on the lungs themselves, AP01 hopes to produce therapeutic effect without the unwanted effects encountered when orally administered products.

Avalyn is also advancing AP02, an inhaled formulation of nintedanib, the antifibrotic compound. Two Phase 1 trials of AP02 have been done, and there were robust tolerability and safety at various doses. Treatment for IPF, a disease with limited treatment alternatives and robust unmet medical need, is under preparation.

By visiting the Citi Biotech Private Access Day, Avalyn aims to gain increased investor participation, highlight its innovative character and build momentum for its in-clinic pipeline. These investor meetings offer an important platform upon which the company can disseminate data insights, lay out tomorrow’s visions, and establish itself as an innovative pulmonary drug pioneer. This achievement is another milestone in the development cycle for Avalyn in bringing targeted, patient-favorable therapies to the market.